| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drugs, Generic | 34 | 2021 | 457 | 8.420 |
Why?
|
| Product Surveillance, Postmarketing | 21 | 2019 | 463 | 5.930 |
Why?
|
| Pharmacoepidemiology | 23 | 2025 | 351 | 4.690 |
Why?
|
| Warfarin | 22 | 2022 | 1494 | 3.470 |
Why?
|
| Drug Approval | 15 | 2018 | 820 | 3.130 |
Why?
|
| Drug Interactions | 18 | 2025 | 1419 | 2.990 |
Why?
|
| Drug Utilization | 14 | 2021 | 1187 | 2.790 |
Why?
|
| Propensity Score | 35 | 2022 | 1973 | 2.640 |
Why?
|
| Anticoagulants | 26 | 2022 | 4857 | 2.640 |
Why?
|
| Drug Substitution | 10 | 2021 | 292 | 2.540 |
Why?
|
| Databases, Factual | 57 | 2021 | 8062 | 2.530 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 15 | 2020 | 497 | 2.110 |
Why?
|
| Research Design | 18 | 2022 | 6206 | 2.010 |
Why?
|
| Medication Adherence | 21 | 2021 | 2190 | 2.000 |
Why?
|
| Drug Prescriptions | 16 | 2021 | 1662 | 1.920 |
Why?
|
| Prescription Drugs | 10 | 2021 | 634 | 1.870 |
Why?
|
| Cross-Over Studies | 12 | 2021 | 2108 | 1.830 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 18 | 2019 | 3249 | 1.690 |
Why?
|
| Antithrombins | 5 | 2021 | 295 | 1.640 |
Why?
|
| Adrenergic beta-Antagonists | 6 | 2018 | 1239 | 1.490 |
Why?
|
| Atrial Fibrillation | 15 | 2021 | 5185 | 1.480 |
Why?
|
| United States Food and Drug Administration | 22 | 2021 | 1673 | 1.470 |
Why?
|
| Epidemiologic Research Design | 5 | 2019 | 368 | 1.420 |
Why?
|
| Electronic Health Records | 18 | 2021 | 4863 | 1.410 |
Why?
|
| Cohort Studies | 66 | 2023 | 41684 | 1.360 |
Why?
|
| Sentinel Surveillance | 6 | 2018 | 292 | 1.350 |
Why?
|
| Angioedema | 5 | 2019 | 184 | 1.350 |
Why?
|
| Gastrointestinal Hemorrhage | 12 | 2020 | 1127 | 1.320 |
Why?
|
| Ticlopidine | 5 | 2017 | 730 | 1.320 |
Why?
|
| Comparative Effectiveness Research | 7 | 2018 | 713 | 1.260 |
Why?
|
| Rare Diseases | 4 | 2015 | 630 | 1.250 |
Why?
|
| Analgesics, Opioid | 13 | 2022 | 3836 | 1.250 |
Why?
|
| Platelet Aggregation Inhibitors | 6 | 2018 | 2768 | 1.190 |
Why?
|
| Rhabdomyolysis | 4 | 2019 | 150 | 1.170 |
Why?
|
| Calcium Channel Blockers | 4 | 2020 | 686 | 1.160 |
Why?
|
| Pyridones | 6 | 2022 | 817 | 1.120 |
Why?
|
| United States | 100 | 2021 | 72920 | 1.110 |
Why?
|
| Computer Simulation | 15 | 2020 | 6254 | 1.100 |
Why?
|
| Patient Preference | 7 | 2020 | 947 | 1.100 |
Why?
|
| Drug Monitoring | 5 | 2018 | 961 | 1.070 |
Why?
|
| Hypolipidemic Agents | 7 | 2018 | 609 | 1.040 |
Why?
|
| Medicare | 20 | 2021 | 6820 | 1.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 6 | 2018 | 1513 | 1.020 |
Why?
|
| Epidemiologic Methods | 6 | 2017 | 1325 | 1.000 |
Why?
|
| Hemorrhage | 13 | 2020 | 3466 | 1.000 |
Why?
|
| Insurance, Health | 8 | 2020 | 2520 | 0.940 |
Why?
|
| Angiotensin Receptor Antagonists | 4 | 2020 | 1060 | 0.940 |
Why?
|
| Humans | 253 | 2025 | 766117 | 0.920 |
Why?
|
| Insurance Claim Review | 8 | 2021 | 744 | 0.900 |
Why?
|
| Baclofen | 2 | 2022 | 121 | 0.900 |
Why?
|
| Biological Products | 4 | 2022 | 947 | 0.890 |
Why?
|
| Therapeutic Equivalency | 9 | 2018 | 135 | 0.890 |
Why?
|
| Anticonvulsants | 6 | 2016 | 1920 | 0.870 |
Why?
|
| Venous Thromboembolism | 6 | 2022 | 1883 | 0.860 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 2 | 2017 | 285 | 0.850 |
Why?
|
| Hypoglycemic Agents | 14 | 2020 | 3107 | 0.850 |
Why?
|
| Comorbidity | 13 | 2022 | 10579 | 0.840 |
Why?
|
| Carisoprodol | 1 | 2022 | 5 | 0.820 |
Why?
|
| Methocarbamol | 1 | 2022 | 8 | 0.820 |
Why?
|
| Drug Evaluation | 2 | 2021 | 642 | 0.820 |
Why?
|
| Aged | 98 | 2023 | 171219 | 0.800 |
Why?
|
| Psoriasis | 2 | 2022 | 922 | 0.800 |
Why?
|
| Tetrazoles | 2 | 2018 | 918 | 0.790 |
Why?
|
| Pyrazoles | 6 | 2022 | 2031 | 0.790 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 9 | 2022 | 2271 | 0.780 |
Why?
|
| Drug Recalls | 2 | 2020 | 20 | 0.780 |
Why?
|
| Ondansetron | 1 | 2022 | 95 | 0.770 |
Why?
|
| Data Mining | 6 | 2021 | 560 | 0.770 |
Why?
|
| Hospitalization | 16 | 2022 | 10811 | 0.770 |
Why?
|
| Insurance, Pharmaceutical Services | 4 | 2020 | 347 | 0.740 |
Why?
|
| Coronary Artery Bypass | 5 | 2017 | 2188 | 0.740 |
Why?
|
| Female | 140 | 2023 | 396233 | 0.720 |
Why?
|
| Male | 133 | 2023 | 363935 | 0.710 |
Why?
|
| Data Interpretation, Statistical | 12 | 2021 | 2689 | 0.710 |
Why?
|
| Prescriptions | 2 | 2022 | 388 | 0.710 |
Why?
|
| Neuromuscular Agents | 1 | 2022 | 148 | 0.700 |
Why?
|
| Lorazepam | 1 | 2021 | 155 | 0.700 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2015 | 1740 | 0.680 |
Why?
|
| Pharmacies | 3 | 2021 | 171 | 0.670 |
Why?
|
| Antihypertensive Agents | 7 | 2019 | 2028 | 0.670 |
Why?
|
| Hyperlipidemias | 5 | 2018 | 770 | 0.650 |
Why?
|
| Arthritis, Psoriatic | 1 | 2022 | 218 | 0.650 |
Why?
|
| Withholding Treatment | 2 | 2021 | 619 | 0.640 |
Why?
|
| Case-Control Studies | 13 | 2021 | 22228 | 0.640 |
Why?
|
| Middle Aged | 98 | 2022 | 223083 | 0.630 |
Why?
|
| Drug Costs | 9 | 2021 | 1195 | 0.620 |
Why?
|
| Blood Loss, Surgical | 2 | 2015 | 642 | 0.610 |
Why?
|
| Risk Assessment | 25 | 2021 | 24276 | 0.610 |
Why?
|
| Marketing | 2 | 2018 | 225 | 0.610 |
Why?
|
| Wet Macular Degeneration | 1 | 2020 | 158 | 0.600 |
Why?
|
| Epilepsy | 5 | 2016 | 3317 | 0.590 |
Why?
|
| Algorithms | 11 | 2022 | 14066 | 0.590 |
Why?
|
| Drug Therapy, Combination | 7 | 2023 | 6309 | 0.580 |
Why?
|
| Delivery, Obstetric | 3 | 2019 | 948 | 0.580 |
Why?
|
| Renal Insufficiency | 2 | 2016 | 810 | 0.570 |
Why?
|
| Trust | 3 | 2017 | 532 | 0.560 |
Why?
|
| Choroidal Neovascularization | 1 | 2020 | 350 | 0.550 |
Why?
|
| Azithromycin | 3 | 2022 | 202 | 0.550 |
Why?
|
| Niacin | 1 | 2017 | 116 | 0.540 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2023 | 3247 | 0.540 |
Why?
|
| Thromboembolism | 3 | 2020 | 1001 | 0.530 |
Why?
|
| International Classification of Diseases | 3 | 2018 | 934 | 0.520 |
Why?
|
| Drug Utilization Review | 1 | 2017 | 248 | 0.520 |
Why?
|
| Ketolides | 2 | 2014 | 12 | 0.520 |
Why?
|
| Acute Coronary Syndrome | 3 | 2018 | 2185 | 0.520 |
Why?
|
| Methylprednisolone | 1 | 2017 | 386 | 0.520 |
Why?
|
| Inappropriate Prescribing | 1 | 2019 | 211 | 0.520 |
Why?
|
| Pharmaceutical Preparations | 5 | 2021 | 1084 | 0.520 |
Why?
|
| Public Opinion | 2 | 2019 | 483 | 0.510 |
Why?
|
| Thiazolidinediones | 2 | 2016 | 460 | 0.500 |
Why?
|
| Intracranial Hemorrhages | 3 | 2018 | 810 | 0.500 |
Why?
|
| Choice Behavior | 2 | 2019 | 846 | 0.490 |
Why?
|
| Peer Review | 1 | 2017 | 217 | 0.490 |
Why?
|
| Parkinson Disease, Secondary | 1 | 2015 | 120 | 0.490 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2020 | 1331 | 0.480 |
Why?
|
| Models, Theoretical | 3 | 2016 | 3561 | 0.480 |
Why?
|
| Stroke | 11 | 2021 | 9748 | 0.480 |
Why?
|
| Private Sector | 1 | 2018 | 396 | 0.470 |
Why?
|
| Diabetes Mellitus | 10 | 2018 | 5889 | 0.470 |
Why?
|
| Aged, 80 and over | 30 | 2022 | 59515 | 0.460 |
Why?
|
| Myocardial Infarction | 11 | 2020 | 11509 | 0.460 |
Why?
|
| Statistics as Topic | 3 | 2018 | 2351 | 0.460 |
Why?
|
| Community Pharmacy Services | 2 | 2018 | 52 | 0.460 |
Why?
|
| Sulfonylurea Compounds | 4 | 2020 | 220 | 0.460 |
Why?
|
| Receptors, Dopamine D3 | 1 | 2014 | 106 | 0.450 |
Why?
|
| Privacy | 1 | 2016 | 232 | 0.450 |
Why?
|
| Compulsive Behavior | 1 | 2014 | 117 | 0.450 |
Why?
|
| Pneumonia | 3 | 2023 | 2159 | 0.440 |
Why?
|
| Obstetric Labor Complications | 2 | 2019 | 239 | 0.440 |
Why?
|
| Health Services | 2 | 2022 | 756 | 0.440 |
Why?
|
| Information Systems | 1 | 2015 | 400 | 0.430 |
Why?
|
| Logistic Models | 14 | 2020 | 13273 | 0.430 |
Why?
|
| Bone Density Conservation Agents | 3 | 2016 | 791 | 0.430 |
Why?
|
| Time Factors | 28 | 2022 | 40108 | 0.420 |
Why?
|
| Incidence | 20 | 2020 | 21513 | 0.420 |
Why?
|
| Cardiovascular Diseases | 12 | 2022 | 15647 | 0.420 |
Why?
|
| Models, Statistical | 7 | 2019 | 5089 | 0.420 |
Why?
|
| Disease | 2 | 2017 | 674 | 0.410 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2019 | 742 | 0.400 |
Why?
|
| Odds Ratio | 10 | 2020 | 9657 | 0.400 |
Why?
|
| Legislation, Drug | 3 | 2021 | 216 | 0.400 |
Why?
|
| Patient Advocacy | 1 | 2015 | 361 | 0.400 |
Why?
|
| Pregnancy Complications | 4 | 2019 | 2970 | 0.400 |
Why?
|
| Thiophenes | 2 | 2014 | 570 | 0.400 |
Why?
|
| Research | 3 | 2017 | 1975 | 0.400 |
Why?
|
| Evidence-Based Medicine | 6 | 2020 | 3690 | 0.390 |
Why?
|
| Gambling | 1 | 2014 | 180 | 0.390 |
Why?
|
| Dopamine Agonists | 1 | 2014 | 346 | 0.390 |
Why?
|
| Proportional Hazards Models | 15 | 2020 | 12529 | 0.390 |
Why?
|
| Drug Therapy | 1 | 2015 | 504 | 0.390 |
Why?
|
| Tamoxifen | 1 | 2016 | 964 | 0.390 |
Why?
|
| Imidazoles | 1 | 2018 | 1169 | 0.380 |
Why?
|
| Severity of Illness Index | 7 | 2020 | 15882 | 0.380 |
Why?
|
| Health Knowledge, Attitudes, Practice | 8 | 2020 | 4054 | 0.380 |
Why?
|
| Models, Biological | 2 | 2018 | 9445 | 0.380 |
Why?
|
| Automation | 1 | 2014 | 585 | 0.380 |
Why?
|
| Thiazoles | 2 | 2021 | 1528 | 0.370 |
Why?
|
| Parkinson Disease | 3 | 2016 | 2885 | 0.370 |
Why?
|
| Antidepressive Agents | 3 | 2019 | 2901 | 0.370 |
Why?
|
| Immunosuppressive Agents | 3 | 2019 | 4213 | 0.360 |
Why?
|
| Dexamethasone | 2 | 2017 | 1962 | 0.360 |
Why?
|
| Simvastatin | 3 | 2020 | 345 | 0.360 |
Why?
|
| Safety | 1 | 2015 | 1157 | 0.360 |
Why?
|
| Oxycodone | 2 | 2022 | 144 | 0.360 |
Why?
|
| Adult | 60 | 2022 | 223139 | 0.350 |
Why?
|
| Smoking | 4 | 2020 | 9082 | 0.340 |
Why?
|
| Italy | 5 | 2017 | 851 | 0.340 |
Why?
|
| Sepsis | 2 | 2022 | 2603 | 0.340 |
Why?
|
| Treatment Outcome | 25 | 2021 | 65219 | 0.340 |
Why?
|
| Clarithromycin | 2 | 2020 | 87 | 0.330 |
Why?
|
| Clinical Coding | 3 | 2021 | 187 | 0.330 |
Why?
|
| Hydrocortisone | 1 | 2017 | 1832 | 0.330 |
Why?
|
| Retrospective Studies | 35 | 2022 | 81565 | 0.330 |
Why?
|
| Forecasting | 1 | 2018 | 2936 | 0.330 |
Why?
|
| International Normalized Ratio | 4 | 2021 | 382 | 0.320 |
Why?
|
| Commerce | 1 | 2014 | 612 | 0.320 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 1204 | 0.320 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 3 | 2016 | 319 | 0.320 |
Why?
|
| Administration, Oral | 8 | 2022 | 4016 | 0.320 |
Why?
|
| Aprotinin | 1 | 2009 | 93 | 0.320 |
Why?
|
| Pyridines | 3 | 2021 | 2889 | 0.320 |
Why?
|
| Reimbursement Mechanisms | 1 | 2014 | 669 | 0.310 |
Why?
|
| Monte Carlo Method | 4 | 2019 | 1238 | 0.310 |
Why?
|
| Cytochrome P-450 CYP3A | 2 | 2019 | 117 | 0.310 |
Why?
|
| Metoprolol | 2 | 2018 | 90 | 0.300 |
Why?
|
| Glipizide | 5 | 2020 | 48 | 0.300 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2016 | 1535 | 0.300 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2018 | 10380 | 0.300 |
Why?
|
| Pharmacists | 3 | 2020 | 261 | 0.300 |
Why?
|
| Length of Stay | 3 | 2017 | 6490 | 0.290 |
Why?
|
| Disease Progression | 3 | 2020 | 13616 | 0.290 |
Why?
|
| Taiwan | 3 | 2019 | 521 | 0.290 |
Why?
|
| Pennsylvania | 4 | 2013 | 615 | 0.290 |
Why?
|
| Pharmaceutical Services | 3 | 2018 | 145 | 0.290 |
Why?
|
| Hypoglycemia | 5 | 2019 | 896 | 0.280 |
Why?
|
| Delivery of Health Care | 4 | 2020 | 5367 | 0.280 |
Why?
|
| New Jersey | 3 | 2013 | 296 | 0.280 |
Why?
|
| Cholesterol | 1 | 2016 | 2902 | 0.280 |
Why?
|
| Fungemia | 1 | 2007 | 57 | 0.280 |
Why?
|
| Benzodiazepines | 3 | 2022 | 1136 | 0.280 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2020 | 1568 | 0.270 |
Why?
|
| Patient Readmission | 2 | 2018 | 3283 | 0.270 |
Why?
|
| Follow-Up Studies | 14 | 2020 | 39243 | 0.270 |
Why?
|
| Piperazines | 2 | 2014 | 2547 | 0.270 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2018 | 2306 | 0.270 |
Why?
|
| Treatment Failure | 1 | 2012 | 2653 | 0.260 |
Why?
|
| Narcotic Antagonists | 2 | 2022 | 591 | 0.260 |
Why?
|
| Bronchodilator Agents | 2 | 2023 | 513 | 0.260 |
Why?
|
| Hemostatics | 1 | 2009 | 247 | 0.260 |
Why?
|
| Medicare Part D | 2 | 2021 | 355 | 0.260 |
Why?
|
| Risk Factors | 30 | 2021 | 74857 | 0.260 |
Why?
|
| Aortic Coarctation | 2 | 2018 | 278 | 0.260 |
Why?
|
| Decision Support Techniques | 2 | 2019 | 2006 | 0.260 |
Why?
|
| Substance-Related Disorders | 1 | 2022 | 4418 | 0.250 |
Why?
|
| Lisinopril | 3 | 2016 | 60 | 0.250 |
Why?
|
| Program Development | 1 | 2012 | 1297 | 0.250 |
Why?
|
| Nebulizers and Vaporizers | 2 | 2023 | 138 | 0.240 |
Why?
|
| Glyburide | 4 | 2020 | 117 | 0.240 |
Why?
|
| Cerebral Hemorrhage | 1 | 2016 | 2649 | 0.240 |
Why?
|
| Metformin | 3 | 2019 | 903 | 0.240 |
Why?
|
| Endpoint Determination | 2 | 2019 | 591 | 0.240 |
Why?
|
| Hospital Mortality | 3 | 2018 | 5340 | 0.240 |
Why?
|
| Sexual Behavior | 1 | 2014 | 2192 | 0.240 |
Why?
|
| Diabetes Mellitus, Type 2 | 8 | 2020 | 12235 | 0.240 |
Why?
|
| Clinical Trials as Topic | 4 | 2015 | 8038 | 0.230 |
Why?
|
| Self Efficacy | 1 | 2009 | 641 | 0.230 |
Why?
|
| Candidiasis | 1 | 2007 | 372 | 0.230 |
Why?
|
| Muscarinic Antagonists | 2 | 2023 | 135 | 0.230 |
Why?
|
| Brain Ischemia | 1 | 2018 | 3002 | 0.230 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 2 | 2023 | 109 | 0.230 |
Why?
|
| Thalidomide | 2 | 2022 | 886 | 0.230 |
Why?
|
| Seizures | 3 | 2016 | 2997 | 0.230 |
Why?
|
| Mortality | 2 | 2017 | 2911 | 0.220 |
Why?
|
| Anti-Bacterial Agents | 7 | 2022 | 7474 | 0.220 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2009 | 1097 | 0.220 |
Why?
|
| Glycopyrrolate | 1 | 2023 | 35 | 0.220 |
Why?
|
| Fractures, Bone | 2 | 2017 | 2041 | 0.220 |
Why?
|
| Information Storage and Retrieval | 2 | 2019 | 831 | 0.210 |
Why?
|
| Young Adult | 19 | 2020 | 59868 | 0.210 |
Why?
|
| Embolism | 2 | 2020 | 401 | 0.210 |
Why?
|
| Medical Records | 2 | 2019 | 1408 | 0.210 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2023 | 1882 | 0.210 |
Why?
|
| Migraine Disorders | 4 | 2009 | 1712 | 0.210 |
Why?
|
| Orphenadrine | 1 | 2022 | 4 | 0.210 |
Why?
|
| Chlorzoxazone | 1 | 2022 | 9 | 0.210 |
Why?
|
| Hypertension | 7 | 2018 | 8616 | 0.210 |
Why?
|
| Hydrocodone | 1 | 2022 | 48 | 0.200 |
Why?
|
| Caregivers | 1 | 2015 | 2304 | 0.200 |
Why?
|
| Fluoroquinolones | 2 | 2022 | 307 | 0.200 |
Why?
|
| Administration, Inhalation | 2 | 2023 | 1154 | 0.200 |
Why?
|
| Antifungal Agents | 1 | 2007 | 769 | 0.200 |
Why?
|
| Amitriptyline | 1 | 2022 | 110 | 0.200 |
Why?
|
| Ciprofloxacin | 3 | 2022 | 314 | 0.190 |
Why?
|
| Monitoring, Physiologic | 1 | 2009 | 1794 | 0.190 |
Why?
|
| Adolescent | 19 | 2022 | 88819 | 0.190 |
Why?
|
| Cardiovascular Agents | 2 | 2018 | 848 | 0.190 |
Why?
|
| Comoros | 1 | 2020 | 12 | 0.180 |
Why?
|
| Deductibles and Coinsurance | 2 | 2021 | 315 | 0.180 |
Why?
|
| Rheumatic Diseases | 2 | 2018 | 657 | 0.180 |
Why?
|
| Denmark | 6 | 2020 | 774 | 0.180 |
Why?
|
| Optometry | 1 | 2020 | 29 | 0.180 |
Why?
|
| Muscle Relaxants, Central | 1 | 2021 | 94 | 0.180 |
Why?
|
| Patient Compliance | 1 | 2011 | 2694 | 0.180 |
Why?
|
| Drug Combinations | 2 | 2018 | 2076 | 0.170 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2010 | 1805 | 0.170 |
Why?
|
| Age Factors | 10 | 2020 | 18386 | 0.170 |
Why?
|
| Fenofibrate | 2 | 2017 | 87 | 0.170 |
Why?
|
| Data Collection | 3 | 2019 | 3318 | 0.170 |
Why?
|
| Cerebrovascular Disorders | 2 | 2018 | 1478 | 0.170 |
Why?
|
| Drug Administration Schedule | 3 | 2018 | 4853 | 0.170 |
Why?
|
| Tablets | 1 | 2020 | 149 | 0.170 |
Why?
|
| Veterans | 1 | 2014 | 2667 | 0.170 |
Why?
|
| Outpatients | 3 | 2017 | 1596 | 0.170 |
Why?
|
| Contracts | 1 | 2020 | 60 | 0.170 |
Why?
|
| Databases as Topic | 2 | 2014 | 472 | 0.170 |
Why?
|
| Risk | 7 | 2020 | 9599 | 0.170 |
Why?
|
| Health Services Research | 3 | 2018 | 1811 | 0.170 |
Why?
|
| Pharmacy | 1 | 2021 | 92 | 0.170 |
Why?
|
| National Health Programs | 2 | 2020 | 444 | 0.170 |
Why?
|
| Vitamin K | 3 | 2020 | 312 | 0.170 |
Why?
|
| Attitude of Health Personnel | 4 | 2020 | 3928 | 0.160 |
Why?
|
| Delayed-Action Preparations | 3 | 2018 | 966 | 0.160 |
Why?
|
| Confidence Intervals | 3 | 2013 | 2915 | 0.160 |
Why?
|
| Control Groups | 1 | 2019 | 107 | 0.160 |
Why?
|
| Heart Failure | 3 | 2019 | 11837 | 0.160 |
Why?
|
| Cost-Benefit Analysis | 4 | 2021 | 5531 | 0.160 |
Why?
|
| Chronic Disease | 4 | 2019 | 9354 | 0.160 |
Why?
|
| Codeine | 2 | 2016 | 52 | 0.160 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2020 | 2255 | 0.160 |
Why?
|
| Urinary Tract Infections | 2 | 2022 | 804 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 6506 | 0.160 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2021 | 451 | 0.160 |
Why?
|
| Lawyers | 1 | 2019 | 39 | 0.160 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 1 | 2018 | 30 | 0.160 |
Why?
|
| Adrenergic Antagonists | 1 | 2018 | 26 | 0.160 |
Why?
|
| Sensitivity and Specificity | 5 | 2020 | 14645 | 0.150 |
Why?
|
| Neoplasms | 10 | 2020 | 22344 | 0.150 |
Why?
|
| Acitretin | 1 | 2018 | 16 | 0.150 |
Why?
|
| Physicians | 1 | 2016 | 4591 | 0.150 |
Why?
|
| Antirheumatic Agents | 2 | 2018 | 1380 | 0.150 |
Why?
|
| Secondary Prevention | 2 | 2018 | 1470 | 0.150 |
Why?
|
| Disease Management | 2 | 2018 | 2531 | 0.150 |
Why?
|
| Drug Repositioning | 1 | 2020 | 245 | 0.150 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2020 | 216 | 0.150 |
Why?
|
| Decision Making | 3 | 2018 | 3955 | 0.150 |
Why?
|
| Incretins | 1 | 2018 | 100 | 0.150 |
Why?
|
| Population Surveillance | 2 | 2018 | 2596 | 0.150 |
Why?
|
| Perception | 3 | 2019 | 1204 | 0.150 |
Why?
|
| Hematinics | 1 | 2020 | 282 | 0.150 |
Why?
|
| Sertraline | 1 | 2019 | 210 | 0.140 |
Why?
|
| Clindamycin | 1 | 2018 | 138 | 0.140 |
Why?
|
| Naloxone | 1 | 2020 | 373 | 0.140 |
Why?
|
| Vulnerable Populations | 2 | 2014 | 717 | 0.140 |
Why?
|
| Ventricular Fibrillation | 1 | 2020 | 538 | 0.140 |
Why?
|
| Social Class | 3 | 2019 | 2007 | 0.140 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2020 | 419 | 0.140 |
Why?
|
| Paroxetine | 2 | 2022 | 181 | 0.140 |
Why?
|
| Sex Factors | 6 | 2020 | 10614 | 0.140 |
Why?
|
| Ventricular Dysfunction | 1 | 2018 | 143 | 0.140 |
Why?
|
| Technology | 1 | 2019 | 296 | 0.140 |
Why?
|
| Reproducibility of Results | 8 | 2022 | 20137 | 0.140 |
Why?
|
| Drug Labeling | 2 | 2016 | 251 | 0.140 |
Why?
|
| Stomach Ulcer | 1 | 2017 | 118 | 0.130 |
Why?
|
| Medication Therapy Management | 1 | 2018 | 131 | 0.130 |
Why?
|
| Organic Cation Transporter 1 | 1 | 2016 | 7 | 0.130 |
Why?
|
| Focus Groups | 4 | 2016 | 1459 | 0.130 |
Why?
|
| Mental Disorders | 1 | 2016 | 6871 | 0.130 |
Why?
|
| Biometry | 1 | 2019 | 571 | 0.130 |
Why?
|
| Erythropoietin | 1 | 2020 | 716 | 0.130 |
Why?
|
| Citalopram | 1 | 2019 | 402 | 0.130 |
Why?
|
| Aortic Aneurysm | 1 | 2020 | 649 | 0.130 |
Why?
|
| Frail Elderly | 1 | 2021 | 782 | 0.130 |
Why?
|
| Guidelines as Topic | 2 | 2019 | 1394 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2018 | 3230 | 0.120 |
Why?
|
| Investments | 1 | 2017 | 148 | 0.120 |
Why?
|
| Depression | 2 | 2022 | 8230 | 0.120 |
Why?
|
| Quality of Health Care | 2 | 2008 | 4306 | 0.120 |
Why?
|
| Likelihood Functions | 1 | 2018 | 993 | 0.120 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2019 | 317 | 0.120 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2017 | 361 | 0.120 |
Why?
|
| Medicaid | 4 | 2020 | 2835 | 0.120 |
Why?
|
| Drug Discovery | 2 | 2015 | 1065 | 0.120 |
Why?
|
| Respiratory System Agents | 1 | 2014 | 30 | 0.120 |
Why?
|
| Eye Diseases | 1 | 2020 | 660 | 0.120 |
Why?
|
| Alendronate | 1 | 2016 | 174 | 0.120 |
Why?
|
| Hemoglobins | 2 | 2020 | 1531 | 0.120 |
Why?
|
| Mental Health | 1 | 2009 | 3273 | 0.120 |
Why?
|
| Cannabinoids | 1 | 2017 | 174 | 0.120 |
Why?
|
| Health Care Surveys | 2 | 2019 | 2426 | 0.110 |
Why?
|
| Natural History | 1 | 2013 | 3 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 4 | 2017 | 7424 | 0.110 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2016 | 746 | 0.110 |
Why?
|
| Bronchitis | 1 | 2014 | 193 | 0.110 |
Why?
|
| Medical Record Linkage | 1 | 2015 | 286 | 0.110 |
Why?
|
| France | 3 | 2020 | 495 | 0.110 |
Why?
|
| Ophthalmology | 1 | 2020 | 559 | 0.110 |
Why?
|
| Natural Language Processing | 2 | 2019 | 1198 | 0.110 |
Why?
|
| Health Expenditures | 4 | 2021 | 2389 | 0.110 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2009 | 3682 | 0.110 |
Why?
|
| Kidney | 1 | 2009 | 7072 | 0.110 |
Why?
|
| Databases, Bibliographic | 1 | 2013 | 128 | 0.110 |
Why?
|
| Postoperative Period | 1 | 2018 | 1820 | 0.110 |
Why?
|
| Biphenyl Compounds | 1 | 2018 | 1019 | 0.110 |
Why?
|
| Confidentiality | 2 | 2014 | 607 | 0.110 |
Why?
|
| Prescription Fees | 1 | 2014 | 153 | 0.110 |
Why?
|
| Orphan Drug Production | 1 | 2013 | 48 | 0.110 |
Why?
|
| Lactones | 1 | 2015 | 316 | 0.110 |
Why?
|
| Hypnotics and Sedatives | 1 | 2021 | 1193 | 0.110 |
Why?
|
| Registries | 4 | 2019 | 8347 | 0.100 |
Why?
|
| Enoxaparin | 1 | 2015 | 391 | 0.100 |
Why?
|
| Meta-Analysis as Topic | 1 | 2018 | 1366 | 0.100 |
Why?
|
| Sulfones | 1 | 2015 | 447 | 0.100 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2013 | 186 | 0.100 |
Why?
|
| Anti-Ulcer Agents | 1 | 2013 | 112 | 0.100 |
Why?
|
| Myocardial Revascularization | 1 | 2016 | 795 | 0.100 |
Why?
|
| Isoxazoles | 1 | 2014 | 233 | 0.100 |
Why?
|
| Adenosine | 1 | 2017 | 813 | 0.100 |
Why?
|
| Stockings, Compression | 1 | 2012 | 36 | 0.100 |
Why?
|
| Emergency Service, Hospital | 4 | 2022 | 7871 | 0.100 |
Why?
|
| Antipsychotic Agents | 3 | 2016 | 3077 | 0.100 |
Why?
|
| Prenatal Diagnosis | 1 | 2019 | 1271 | 0.100 |
Why?
|
| Leisure Activities | 1 | 2014 | 310 | 0.100 |
Why?
|
| Quality of Life | 3 | 2015 | 13468 | 0.100 |
Why?
|
| Drug Industry | 1 | 2018 | 791 | 0.100 |
Why?
|
| Histamine H2 Antagonists | 1 | 2013 | 168 | 0.100 |
Why?
|
| Socioeconomic Factors | 5 | 2020 | 7843 | 0.100 |
Why?
|
| Rheumatology | 1 | 2018 | 620 | 0.100 |
Why?
|
| Health Planning Guidelines | 1 | 2012 | 151 | 0.100 |
Why?
|
| Sulfonamides | 2 | 2014 | 1980 | 0.100 |
Why?
|
| Cephalosporins | 1 | 2013 | 200 | 0.100 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2013 | 299 | 0.100 |
Why?
|
| Prospective Studies | 8 | 2019 | 54812 | 0.100 |
Why?
|
| beta-Alanine | 1 | 2012 | 83 | 0.100 |
Why?
|
| Methotrexate | 1 | 2018 | 1719 | 0.090 |
Why?
|
| Primary Health Care | 2 | 2019 | 4736 | 0.090 |
Why?
|
| Medical Informatics Applications | 1 | 2013 | 180 | 0.090 |
Why?
|
| Suicide | 1 | 2022 | 1606 | 0.090 |
Why?
|
| Glomerular Filtration Rate | 2 | 2018 | 2232 | 0.090 |
Why?
|
| Consumer Health Information | 1 | 2014 | 215 | 0.090 |
Why?
|
| Life Change Events | 1 | 2016 | 956 | 0.090 |
Why?
|
| Osteoporotic Fractures | 1 | 2016 | 415 | 0.090 |
Why?
|
| Anemia | 1 | 2020 | 1514 | 0.090 |
Why?
|
| Clostridium Infections | 1 | 2018 | 563 | 0.090 |
Why?
|
| Cholesterol, HDL | 1 | 2017 | 1813 | 0.090 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2013 | 264 | 0.090 |
Why?
|
| Diarrhea | 1 | 2018 | 1315 | 0.090 |
Why?
|
| Quinolones | 1 | 2014 | 389 | 0.090 |
Why?
|
| False Negative Reactions | 1 | 2012 | 570 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2017 | 10737 | 0.090 |
Why?
|
| Primary Prevention | 1 | 2018 | 1187 | 0.090 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2012 | 345 | 0.090 |
Why?
|
| Interview, Psychological | 1 | 2013 | 811 | 0.090 |
Why?
|
| Regression Analysis | 2 | 2016 | 6324 | 0.090 |
Why?
|
| British Columbia | 1 | 2010 | 238 | 0.080 |
Why?
|
| Pregnancy | 5 | 2019 | 30233 | 0.080 |
Why?
|
| Vancomycin | 1 | 2013 | 504 | 0.080 |
Why?
|
| Celiac Disease | 1 | 2018 | 820 | 0.080 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2010 | 77 | 0.080 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2010 | 171 | 0.080 |
Why?
|
| Recurrence | 2 | 2022 | 8494 | 0.080 |
Why?
|
| Prognosis | 5 | 2022 | 29912 | 0.080 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 1480 | 0.080 |
Why?
|
| False Positive Reactions | 1 | 2012 | 956 | 0.080 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 2727 | 0.080 |
Why?
|
| Equipment and Supplies | 1 | 2012 | 273 | 0.080 |
Why?
|
| Morpholines | 1 | 2012 | 584 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 21074 | 0.080 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2011 | 427 | 0.080 |
Why?
|
| Benchmarking | 1 | 2015 | 1055 | 0.080 |
Why?
|
| Canada | 1 | 2014 | 2120 | 0.080 |
Why?
|
| Information Dissemination | 2 | 2014 | 1142 | 0.080 |
Why?
|
| Community Health Centers | 1 | 2012 | 469 | 0.080 |
Why?
|
| Exercise | 2 | 2016 | 5939 | 0.080 |
Why?
|
| Child | 6 | 2019 | 80573 | 0.080 |
Why?
|
| Inpatients | 2 | 2017 | 2566 | 0.080 |
Why?
|
| Aminophylline | 1 | 2008 | 41 | 0.080 |
Why?
|
| Immunologic Factors | 1 | 2017 | 1592 | 0.080 |
Why?
|
| Publication Bias | 1 | 2009 | 157 | 0.080 |
Why?
|
| Intracranial Aneurysm | 1 | 2018 | 1271 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 2017 | 2156 | 0.070 |
Why?
|
| Fluvoxamine | 1 | 2008 | 77 | 0.070 |
Why?
|
| Proton Pump Inhibitors | 1 | 2013 | 551 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 1 | 2013 | 1729 | 0.070 |
Why?
|
| Antiviral Agents | 1 | 2020 | 3068 | 0.070 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 1321 | 0.070 |
Why?
|
| Physicians, Primary Care | 1 | 2014 | 622 | 0.070 |
Why?
|
| Theophylline | 1 | 2008 | 132 | 0.070 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2013 | 641 | 0.070 |
Why?
|
| Barbiturates | 1 | 2008 | 113 | 0.070 |
Why?
|
| Papillomavirus Vaccines | 1 | 2014 | 495 | 0.070 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 1885 | 0.070 |
Why?
|
| Cross-Sectional Studies | 8 | 2020 | 26290 | 0.070 |
Why?
|
| Fluorobenzenes | 1 | 2009 | 179 | 0.070 |
Why?
|
| Benzimidazoles | 1 | 2012 | 862 | 0.070 |
Why?
|
| Risk Adjustment | 1 | 2011 | 597 | 0.070 |
Why?
|
| Memory | 1 | 2016 | 2192 | 0.070 |
Why?
|
| Economic Competition | 2 | 2021 | 223 | 0.070 |
Why?
|
| Software | 2 | 2018 | 4463 | 0.070 |
Why?
|
| Self Report | 2 | 2020 | 3769 | 0.070 |
Why?
|
| Pain | 2 | 2022 | 5090 | 0.070 |
Why?
|
| Postpartum Period | 1 | 2013 | 1195 | 0.070 |
Why?
|
| Drug Design | 1 | 2011 | 1040 | 0.070 |
Why?
|
| Acute Disease | 2 | 2014 | 7237 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 4342 | 0.070 |
Why?
|
| Stents | 1 | 2018 | 3191 | 0.070 |
Why?
|
| Intention to Treat Analysis | 2 | 2018 | 418 | 0.070 |
Why?
|
| Weight Loss | 1 | 2018 | 2711 | 0.060 |
Why?
|
| Attitude to Health | 1 | 2015 | 2020 | 0.060 |
Why?
|
| Smoking Cessation | 2 | 2015 | 2084 | 0.060 |
Why?
|
| Informed Consent | 1 | 2012 | 1010 | 0.060 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 14747 | 0.060 |
Why?
|
| Pilot Projects | 5 | 2018 | 8724 | 0.060 |
Why?
|
| Occupational Diseases | 1 | 2014 | 1456 | 0.060 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 13635 | 0.060 |
Why?
|
| Qualitative Research | 4 | 2018 | 3138 | 0.060 |
Why?
|
| Health Benefit Plans, Employee | 1 | 2008 | 332 | 0.060 |
Why?
|
| Polysaccharides | 1 | 2012 | 1017 | 0.060 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2008 | 336 | 0.060 |
Why?
|
| Absenteeism | 1 | 2007 | 247 | 0.060 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2020 | 3186 | 0.060 |
Why?
|
| Quinolines | 1 | 2011 | 769 | 0.060 |
Why?
|
| Child, Preschool | 4 | 2019 | 42511 | 0.060 |
Why?
|
| Thyroid Neoplasms | 1 | 2018 | 2354 | 0.060 |
Why?
|
| Ischemia | 1 | 2014 | 1904 | 0.060 |
Why?
|
| Survival Rate | 3 | 2018 | 12827 | 0.060 |
Why?
|
| Fructose | 1 | 2007 | 285 | 0.060 |
Why?
|
| Medical Oncology | 1 | 2017 | 2339 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 15403 | 0.060 |
Why?
|
| Anticholesteremic Agents | 1 | 2012 | 970 | 0.060 |
Why?
|
| Medicare Part C | 2 | 2021 | 335 | 0.060 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 2419 | 0.060 |
Why?
|
| Patient-Centered Care | 1 | 2014 | 1447 | 0.060 |
Why?
|
| Stroke Volume | 1 | 2018 | 5595 | 0.060 |
Why?
|
| Life Style | 1 | 2016 | 3928 | 0.060 |
Why?
|
| Evidence-Based Practice | 2 | 2018 | 499 | 0.060 |
Why?
|
| Pulmonary Embolism | 1 | 2017 | 2596 | 0.060 |
Why?
|
| Erythrocyte Transfusion | 1 | 2009 | 574 | 0.060 |
Why?
|
| Parents | 1 | 2018 | 3591 | 0.060 |
Why?
|
| Cross Infection | 1 | 2013 | 1427 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2020 | 4282 | 0.060 |
Why?
|
| Multiple Sclerosis | 1 | 2019 | 3212 | 0.050 |
Why?
|
| Efficiency | 1 | 2007 | 479 | 0.050 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 1544 | 0.050 |
Why?
|
| Communication | 1 | 2018 | 3909 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 3665 | 0.050 |
Why?
|
| Prevalence | 2 | 2018 | 15827 | 0.050 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2017 | 2431 | 0.050 |
Why?
|
| Norfloxacin | 1 | 2022 | 24 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2020 | 13046 | 0.050 |
Why?
|
| Publishing | 1 | 2010 | 836 | 0.050 |
Why?
|
| Pediatrics | 1 | 2016 | 3609 | 0.050 |
Why?
|
| Headache | 1 | 2009 | 1259 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 5454 | 0.040 |
Why?
|
| Fetus | 1 | 2008 | 1878 | 0.040 |
Why?
|
| Epoetin Alfa | 1 | 2020 | 78 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 2 | 2008 | 1804 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 8725 | 0.040 |
Why?
|
| Naltrexone | 1 | 2003 | 319 | 0.040 |
Why?
|
| Postoperative Complications | 2 | 2013 | 15808 | 0.040 |
Why?
|
| Neuroprotective Agents | 1 | 2007 | 959 | 0.040 |
Why?
|
| Osteoporosis | 1 | 2010 | 1582 | 0.040 |
Why?
|
| Massachusetts | 3 | 2021 | 8882 | 0.040 |
Why?
|
| Health Education | 1 | 2006 | 1060 | 0.040 |
Why?
|
| Infant | 2 | 2019 | 36427 | 0.040 |
Why?
|
| Insurance Carriers | 1 | 2021 | 159 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2009 | 1791 | 0.040 |
Why?
|
| Cognition Disorders | 1 | 2013 | 3966 | 0.040 |
Why?
|
| Toluidines | 1 | 2019 | 21 | 0.040 |
Why?
|
| Crotonates | 1 | 2019 | 21 | 0.040 |
Why?
|
| Complementary Therapies | 1 | 2003 | 486 | 0.040 |
Why?
|
| Telemedicine | 1 | 2016 | 3108 | 0.040 |
Why?
|
| Hydroxybutyrates | 1 | 2019 | 75 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2018 | 6544 | 0.040 |
Why?
|
| Multiple Myeloma | 1 | 2016 | 5189 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2019 | 26381 | 0.040 |
Why?
|
| Glucagon-Like Peptides | 1 | 2020 | 157 | 0.040 |
Why?
|
| Terminology as Topic | 2 | 2017 | 1536 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 1 | 2008 | 2171 | 0.040 |
Why?
|
| Fluoxetine | 1 | 2022 | 732 | 0.040 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2020 | 287 | 0.040 |
Why?
|
| Cost Sharing | 1 | 2021 | 409 | 0.040 |
Why?
|
| Aging | 1 | 2016 | 8723 | 0.040 |
Why?
|
| Remote Consultation | 1 | 2020 | 241 | 0.040 |
Why?
|
| Sample Size | 1 | 2021 | 843 | 0.040 |
Why?
|
| Isotretinoin | 1 | 2019 | 135 | 0.040 |
Why?
|
| Validation Studies as Topic | 1 | 2017 | 162 | 0.030 |
Why?
|
| California | 1 | 2021 | 1435 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 2009 | 3712 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2009 | 3853 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2009 | 3050 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2016 | 5946 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2020 | 1638 | 0.030 |
Why?
|
| Brain Infarction | 1 | 2018 | 285 | 0.030 |
Why?
|
| Community Health Planning | 1 | 2016 | 164 | 0.030 |
Why?
|
| Budgets | 1 | 2017 | 233 | 0.030 |
Why?
|
| Coronary Disease | 1 | 2010 | 5919 | 0.030 |
Why?
|
| Phenprocoumon | 1 | 2014 | 19 | 0.030 |
Why?
|
| Insurance Benefits | 1 | 2016 | 186 | 0.030 |
Why?
|
| Patient Simulation | 1 | 2017 | 301 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2016 | 507 | 0.030 |
Why?
|
| Health Care Rationing | 1 | 2018 | 435 | 0.030 |
Why?
|
| Dermatologic Agents | 1 | 2019 | 314 | 0.030 |
Why?
|
| United States Dept. of Health and Human Services | 1 | 2014 | 88 | 0.030 |
Why?
|
| Health Promotion | 1 | 2006 | 2209 | 0.030 |
Why?
|
| Interviews as Topic | 3 | 2008 | 2741 | 0.030 |
Why?
|
| Computer Communication Networks | 1 | 2016 | 292 | 0.030 |
Why?
|
| Probability | 1 | 2019 | 2475 | 0.030 |
Why?
|
| Continuity of Patient Care | 1 | 2021 | 1075 | 0.030 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2014 | 104 | 0.030 |
Why?
|
| Tramadol | 1 | 2014 | 63 | 0.030 |
Why?
|
| Opioid-Related Disorders | 2 | 2020 | 2177 | 0.030 |
Why?
|
| Professional Role | 1 | 2017 | 314 | 0.030 |
Why?
|
| Nausea | 1 | 2017 | 679 | 0.030 |
Why?
|
| Physician-Patient Relations | 2 | 2018 | 3270 | 0.030 |
Why?
|
| Professional-Family Relations | 1 | 2018 | 500 | 0.030 |
Why?
|
| Policy | 1 | 2017 | 512 | 0.030 |
Why?
|
| Nitriles | 1 | 2019 | 981 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 6961 | 0.030 |
Why?
|
| Pathology, Molecular | 1 | 2016 | 329 | 0.030 |
Why?
|
| Diabetic Angiopathies | 1 | 2018 | 805 | 0.030 |
Why?
|
| Standard of Care | 1 | 2017 | 568 | 0.020 |
Why?
|
| Suicidal Ideation | 1 | 2022 | 1466 | 0.020 |
Why?
|
| Peptic Ulcer | 1 | 2013 | 214 | 0.020 |
Why?
|
| Community-Based Participatory Research | 1 | 2014 | 223 | 0.020 |
Why?
|
| ROC Curve | 1 | 2019 | 3614 | 0.020 |
Why?
|
| Nurse Practitioners | 1 | 2014 | 270 | 0.020 |
Why?
|
| Drug Carriers | 1 | 2016 | 701 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2020 | 3733 | 0.020 |
Why?
|
| Computer Security | 1 | 2013 | 261 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 6493 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2016 | 698 | 0.020 |
Why?
|
| Causality | 1 | 2017 | 1247 | 0.020 |
Why?
|
| Chemoprevention | 1 | 2013 | 327 | 0.020 |
Why?
|
| Age Distribution | 1 | 2016 | 2865 | 0.020 |
Why?
|
| Rupture | 1 | 2012 | 444 | 0.020 |
Why?
|
| Creatinine | 1 | 2016 | 1916 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 13483 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2022 | 1937 | 0.020 |
Why?
|
| Government Regulation | 1 | 2014 | 525 | 0.020 |
Why?
|
| Analgesics | 1 | 2017 | 1067 | 0.020 |
Why?
|
| Europe | 1 | 2017 | 3430 | 0.020 |
Why?
|
| Alzheimer Disease | 1 | 2011 | 8724 | 0.020 |
Why?
|
| Achilles Tendon | 1 | 2012 | 181 | 0.020 |
Why?
|
| Hospitals | 1 | 2022 | 3887 | 0.020 |
Why?
|
| Income | 1 | 2017 | 1874 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 12061 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2012 | 878 | 0.020 |
Why?
|
| Motivation | 1 | 2018 | 2019 | 0.020 |
Why?
|
| Patient Participation | 1 | 2017 | 1447 | 0.020 |
Why?
|
| Acute Kidney Injury | 1 | 2020 | 1943 | 0.020 |
Why?
|
| Dyslipidemias | 1 | 2015 | 871 | 0.020 |
Why?
|
| Cause of Death | 1 | 2018 | 3715 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2003 | 4746 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2018 | 2662 | 0.020 |
Why?
|
| Patient Selection | 1 | 2018 | 4249 | 0.020 |
Why?
|
| Boston | 1 | 2019 | 9335 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2013 | 1405 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2018 | 3465 | 0.020 |
Why?
|
| Liver | 1 | 2020 | 7559 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2012 | 987 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2017 | 3955 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2014 | 2235 | 0.010 |
Why?
|
| Glucose | 1 | 2016 | 4335 | 0.010 |
Why?
|
| Health Surveys | 1 | 2014 | 4058 | 0.010 |
Why?
|
| Psychometrics | 1 | 2013 | 3060 | 0.010 |
Why?
|
| Curriculum | 1 | 2016 | 3784 | 0.010 |
Why?
|
| Genome, Human | 1 | 2016 | 4443 | 0.010 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 1637 | 0.010 |
Why?
|
| Linear Models | 1 | 2011 | 5873 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 2844 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2016 | 4859 | 0.010 |
Why?
|
| Animals | 2 | 2012 | 168800 | 0.010 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 3407 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2006 | 2116 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2011 | 8532 | 0.010 |
Why?
|
| Health Behavior | 1 | 2006 | 2649 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 18076 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2007 | 12426 | 0.010 |
Why?
|